Berlin  — Thermo Fisher Scientific raised its bid for diagnostic technology firm Qiagen by €900m on Thursday in an effort to rescue a deal that some of the German genetic test maker's shareholders said undervalued the company's prospects.

The laboratory equipment supplier said it had lifted its bid to €43 a share from €39, representing a 35% premium to Qiagen's closing price when it made the initial offer on March 2...

Subscribe now to unlock this article.

Support BusinessLIVE’s award-winning journalism for R129 per month (digital access only).

There’s never been a more important time to support independent journalism in SA. Our subscription packages now offer an ad-free experience for readers.

Cancel anytime.

Would you like to comment on this article?
Sign up (it's quick and free) or sign in now.

Speech Bubbles

Please read our Comment Policy before commenting.